產(chǎn)品屬性：

Cas No.544467-07-4

別名

化學(xué)名 (Z)-4-[3-(azidomethyl)phenyl]-4-hydroxy-2-oxobut-3-enoic acid

分子式 C11H9N3O4

分子量 247.21

溶解度 Soluble in DMSO

儲存條件 Store at -20°C
General tips  For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition     Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述：
HIV-1 integrase inhibitor is useful for anti-HIV, with IC50 value of 0.33 μM,[1] which can target HIV-1 integrase and depress the activity in the treatment of HIV infection, AIDS, and other similar diseases characterized by integration of a retroviral genome into a host chromosome.

HIV integrase is a 32 kDa protein produced from the C-terminal portion of the Pol gene product, an enzyme produced by HIV that enables its genetic material to be integrated into the DNA of the infected cell [2]which are not to be confused with phage integrases and a key component in the retroviral pre-integration complex (PIC)[3]. HIV-1 integrase is composed of 3 structurally independent, functional domains: the N-terminal domain (NTD),  catalytic core domain (CCD) and the C-terminal domain (CTD).The HIV-1 integration occurs through a multistep process that includes two catalytic reactions: 3'endonucleolytic processing of proviral DNA ends (termed 3'processing) and integration of 3'-processed viral DNA into cellular DNA (referred to as strand transfer)[4].

The human immunodeficiency virus (HIV) is the causative agent for the acquired immunodeficiency syndrome (AIDS)[5], then HIV integrase is an attractive target for new anti-HIV drugs. The drug design of HIV-1 integrase inhibitor include integrase strand transfer inhibitors (INSTIs),inhibition of the LEDGF/p75- integrase interaction and integrase binding inhibitors, but strand transfer inhibition is the most intuitively obvious and readily pursued to date.Mg2+ and Mn2+ are critical cofactors in the integration phase, so removing these cofactors (e.g. through chelation) causes functional impairment of integrase[6].Competitive inhibitors compete directly with viral DNA for binding to integrase in order to inhibit 3‘-end processing.[7] In doing this the inhibitors completely block the active site from binding to target DNA.INSTIs bind tightly and specifically to the IN that is associated with the ends of the DNA by chelating the divalent metal ions (Mg2+) which is coordinated by the catalytic triad, such as the DDE motif which is located in the CCD and is the active site of the enzyme[8].

Development of a successful INSTI treatment was accomplished when raltegravir was discovered by Merck Sharp & Dohme Limited.[9] S/GSK1349572 is an integrase inhibitor discovered by ViiV/Shinongi which was entering phase three in clinical trials in 2011. This new drug is promising and seems to be well tolerated and so far shows better results than both raltegravir and elvitegravir.[10]